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Introduction
Statins are commonly prescribed in clinical 
practice [1]. They are well tolerated and effec-
tively prevent cardiovascular (CV) events [1–3]. 
However, some controversy remains regarding 
the clinical benefits of statins in primary preven-
tion patients with low and moderate CV risk (e.g. 
CV benefit and risk of new onset diabetes (NOD)) 
[4] as well as high-risk patients (e.g. relatively 
low use of high doses of statins) [1]. Taking the 
latter into account, the current American College 
of Cardiology (ACC)/American Heart Association 
(AHA) guidelines support widespread statin use 
and more intensive statin therapy [1]. The new 
Pooled Cohort Risk calculator may result in a larg-
er population qualifying for statin therapy (com-
bination therapy is practically not mentioned); 
this has been a matter of debate [5, 6]. If more 
patients start statin therapy because of overesti-
mated risk this might be a reason for more cases 
of statin non-adherence due to treatment-related 
side effects [7].
Most adverse effects (AEs) associated with sta-
tin therapy are muscle-related. We can find defi-
nitions like: statin-associated myalgia/myopathy, 
statin-induced myalgia/myopathy or statin-related 
myalgia/myopathy (or muscle symptoms (SAMS)) 
[7–9]. The most recent statement of the Euro-
pean Atherosclerosis Society (EAS) has focused 
on SAMS, and avoided the use of the term ‘sta-
tin intolerance’, as it is not specific for muscle 
symptoms [10]. Although muscle syndromes are 
the most common adverse effects observed after 
statin therapy, excluding other side effects might 
underestimate the number of patients with true 
statin intolerance [7].
Statin intolerance is the inability to tolerate 
a dose of statin required to reduce a person’s CV 
risk sufficiently from their baseline risk and could 
result from different statin related side effects in-
cluding: muscle symptoms, headache, sleep dis-
orders, dyspepsia, nausea, rash, alopecia, erectile 
dysfunction, gynecomastia, and/or arthritis. The 
prevalence of statin intolerance is the subject of 
considerable discussion. It seems that this phe-
nomenon might occur in 10–15% of patients [11, 
12], however only very few (< 1%) develop seri-
ous side-effects such as myopathy, myositis or 
rhabdomyolysis [12]. In randomized controlled 
trials (RCTs), the incidence of statin myopathy is 
≤ 5% (usually about 3%) [13]. This low incidence 
is misleading for several reasons. In most studies 
patients with a history of any statin-related side 
effects were excluded. Moreover, patients who are 
at risk of developing muscle-related symptoms, 
such as women, elderly patients, and patients 
with significant comorbidities (e.g. liver failure, 
kidney failure or thyroid disease) are underrepre-
sented in RCTs. In addition, some studies ignored 
statin-associated myalgia and only considered 
elevated serum creatine kinase (CK) activity as 
a side effect [14].
In clinical practice, statin intolerance limits ef-
fective treatment of patients at risk of, or with, 
CV disease (CVD). Physicians face the dilemma of 
whether to continue statins or use other lipid low-
ering drugs [10]. Knowledge of the most common 
adverse effects of statin therapy that might cause 
statin intolerance and the clear definition of this 
phenomenon is crucial to effectively treat patients 
with lipid disorders. Therefore, the aim of this po-
sition paper was to suggest a unified definition of 
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statin intolerance, and to complement the recent 
EAS statement on SAMS, where both pathophysi-
ology, diagnosis and the management were com-
prehensively presented [10]. 
Statin-related adverse effects 
Statin toxicity became of general public inter-
est in 2001, when cerivastatin was withdrawn 
from the market (52 deaths from rhabdomyoly-
sis) although rhabdomyolysis was not observed in 
a meta-analysis of cerivastatin clinical trials [15, 
16]. Such side effects can impair the quality of 
life, adherence to treatment, and in extreme cas-
es, may lead to death. Therefore, uncovering the 
mechanisms by which statins might lead to side 
effects is of great urgency.
There is some disagreement whether choles-
terol-lowering properties of statins might lead to 
their toxicity. According to available data, side 
effects are class-dependent, dose-dependent, 
time-dependent, age-, gender- and co-morbidity 
dependent, and/or dependent on co-treatment 
with certain drugs or foods (e.g. intake of grape-
fruit juice > 1 l/day) [10–14, 17]. Known risk 
factors (endogenous, exogenous) predisposing 
to clinically relevant side-effects include: high-
dose statin therapy, advanced age (> 70 years), 
female sex, family history of muscle disorders, 
history of CK elevation, vitamin D deficiency, 
renal and hepatic impairment, previous history 
of muscle toxicity with another lipid-lowering 
therapy, untreated hypothyroidism, disorders of 
calcium homeostasis, alcohol abuse, Asian eth-
nicity, low body mass index (BMI), genetic poly-
morphisms (e.g. genes associated with drug and 
muscle metabolism), surgery with severe meta-
bolic demands, heavy and/or unaccustomed ex-
ercise and interactions with concomitant medi-
cation [18]. This has been extensively presented 
in the recent EAS statement on SAMS [10], how-
ever it might be useful to consider some of the 
populations at risk of statin intolerance in more 
detail (see below). 
Muscle-related side effects 
Statin-related side effects in 90% of all cases 
appear in first 6 months after initiation of the 
treatment or dose up-titration, and in about 75% 
in the first 10–12 weeks [19]. The most common 
statin-related adverse event is muscle weakness, 
however, due to the many potential reasons for 
this symptom, it is sometimes difficult to definite-
ly state that it is indeed statin-related [10–13]. 
The clinical features of SAMS include symp-
toms such as muscle aches or myalgia, weak-
ness, stiffness, and cramps [20]. According to the 
available data, statins might cause myalgia in 
3–5% patients, myopathy in 0.1–0.2% and rhab-
domyolysis in 0.01% patients [13, 20]. Myopathy 
or myositis is usually defined as a diffuse muscle 
symptom that accompanies elevation of plasma 
CK activity 10-times higher than the upper lim-
it of normal (ULN). It is generally marked by the 
presence of pain, tenderness, weakness due to 
severe pain and restriction in mobility. However, 
it is worth emphasizing that statin-associated 
myopathy may or may not be associated with el-
evations in CK activity. Patients with normal CK 
activity were also reported to develop myopathic 
symptoms with statin therapy, indicating that as-
sessment of CK alone cannot adequately predict 
statin-associated myopathy [20, 21]. Muscle pain 
in patients taking statins could also occur due 
to the structural damage of muscle fibers in the 
absence of elevated CK activity. Rhabdomyolysis 
is characterized by marked elevation of CK ac-
tivity > 50-fold, myoglobinemia, myoglobinuria, 
and myoglobin-induced acute renal failure (ol-
iguria, increased plasma creatinine, potassium 
and phosphorus) [10, 20–22]. According to the 
National Lipid Association (NLA) clinical rhabdo-
myolysis has been defined as severe myonecro-
sis with myoglobinuria or acute renal failure (in-
crease in serum creatinine ≥ 0.5 mg/dl) [10, 20]. 
It is a  more aggressive and severe form of sta-
tin-induced myopathy, resulting in severe skeletal 
muscle injury, lysis, and excretion of dark brown 
urine (indicating presence of excess myoglobin) 
[18–20]. Rhabdomyolysis has an approximately 
10% risk of death due to hyperkalemia-induced 
arrhythmias or disseminated intravascular coag-
ulation [18–20]. 
There are also some differences concerning 
the prevalence of SAMS with different statin 
formulations [20]. According to the available 
data it seems that patients taking simvastatin, 
atorvastatin (18.2, 9.4–14.9% according to PRe-
dIction of Muscular risk in Observational con-
ditions (PRIMO) survey [23] and the Effects of 
Statins on Muscle Performance (STOMP) study 
[24], retrospectively) and lovastatin might be at 
the highest risk of SAMS. The risk of myopathy 
was suggested to be lowest with pravastatin 
(10.9%) and fluvastatin (5.1%), possibly because 
they are more hydrophilic and as a  result have 
less muscle penetration [23]. Individuals on lo-
vastatin, simvastatin (7 cases in the Study of the 
Effectiveness of Additional Reductions in Choles-
terol and Homocysteine (SEARCH) Collaborative 
Group [25], and 7 in the Heart Protection Study 
2-Treatment of HDL to Reduce the Incidence of 
Vascular Events (HPS2-THRIVE) trial [26]) and 
atorvastatin therapy reported higher incidences 
of rhabdomyolysis. This was due to higher rate 
of statin metabolism by hepatic microsomal en-
zymes, cytochrome P3A450 (CYP) isoenzymes. 
Concurrent use of statins with these medications 
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significantly increases the risk of rhabdomyoly-
sis compared with monotherapy; the higher risk 
is more often reported in statin-fibrate combi-
nations than in statin-niacin combinations [18–
20]. In general, these muscle effects have been 
reported more with the use of synthetic, potent 
and more lipophilic statins [18–20].
Expert opinion
The authors of this position paper support 
the recent EAS Consensus Panel Statement on 
Assessment, Aetiology and Management of sta-
tin-associated muscle symptoms (SAMS).
Hepatotoxicity 
An asymptomatic rise in hepatic enzyme activ-
ity is one of the most common AEs of statin ther-
apy – the incidence of elevated aminotransferase 
activity > 3 times ULN is typically no greater than 
3% [27]. The elevation of aminotransferases usu-
ally returns to normal after a dose reduction with-
out the need for statin discontinuation (in some 
cases it is possible to return to the initial doses of 
statins after 2–4 weeks) [10–13]. 
Whereas statin-induced hepatotoxicity is rare 
but may be present as asymptomatic elevation of 
serum transaminases (0.5–2% of patients treated), 
hepatitis, cholestasis and acute liver failure. The 
proposed mechanisms of statin-induced hepato-
toxicity include induction of caspase activity, trig-
gering of apoptosis, reduction of coenzyme Q10 
(ubiquinone, CoQ10) and generation of free rad-
icals [18, 20]. However, it is still not clear wheth-
er (and how) statins cause any kind of significant 
liver injury or liver failure. A recent analysis of the 
Swedish Adverse Drug Reactions Advisory Com-
mittee estimated the incidence of statin-related 
transaminitis at 1.2 per 100,000 patients taking 
statins. The liver abnormalities were mostly seen 
after 3 to 4 months of treatment, and atorvas-
tatin and simvastatin were the most responsible 
agents [28]. Statin-induced jaundice is calculated 
at a  risk of 1 in 17,434 users per year, based on 
a  population in Iceland [29]. Periodic monitoring 
of liver enzyme activity seems not to be useful in 
either detecting or preventing serious liver injury, 
thus justifying the discontinuation of the previous 
recommendation for routine, serial liver enzyme 
monitoring during chronic statin therapy [30]. Ac-
cording to statement from 28th February 2012 the 
Food and Drug Administration (FDA) recommends 
checking liver function tests at baseline and later 
as clinically warranted [31].
Expert opinion
The authors of this position paper support 
FDA recommendation to analyze aminotrans-
ferases before starting statin therapy and as 
clinically indicated thereafter (e.g. if AEs appear 
during the therapy).
New onset diabetes mellitus
Statin therapy may increase the risk of NOD; 
this association is observed for all investigated 
statins (hydrophilic or lipophilic), thus possibly 
representing a  class effect [32, 33]. At least few 
mechanisms may contribute to causing NOD as-
sociated with statin therapy [34]. In recent years 
there has been a  debate regarding the clinical 
implications of this phenomenon – whether and 
when we should start treatment, in what groups 
we should continue, stop it, or reduce the statin 
dose, and which groups of patients are at the 
highest risk of NOD [33, 35].
This debate began few years ago after the 
publication of the meta-analysis [36], which re-
vealed that statin therapy for a mean follow-up 
of 4 years was associated with a  higher inci-
dence (by 9%) of NOD. The risk of development 
of NOD with  statins  was highest in trials  with 
older participants, but neither baseline BMI nor 
change in low density lipoprotein cholesterol 
(LDL-C) concentrations accounted for variation 
in risk [36]. The next meta-analysis reported an 
even higher – 13% increase in the risk of NOD 
[37]. Preiss et al. in their meta-analysis [38] con-
cluded that although high-dose statin therapy 
compared with moderate-dose statin therapy 
was associated with a higher incidence of NOD 
(by 12%), it was also related to significant reduc-
tion in major CV events (by 16%). They showed 
that intense statin treatment is beneficial since 
it significantly outweighs the risks of NOD. There 
was one additional case of type 2 diabetes mel-
litus (T2DM) for every 498 patients treated for 
1 year compared with 1 fewer patient experienc-
ing a CV event for every 155 patients treated for 
1 year [38]. The benefits of statin therapy, which 
outweighs NOD risk, have been also observed 
in the primary prevention studies. The analy-
sis of the Justification for the Use of Statins in 
Prevention: an Intervention Trial Evaluating Ro-
suvastatin (JUPITER) study [39] demonstrated 
that in participants with and without diabetes 
risk factors, the overall beneficial effect of statin 
therapy on vascular events was greater (almost 
2.5-fold) than the hazard of developing NOD, and 
this effect was observed even in a lower-risk pri-
mary-prevention population [39]. On the basis 
of the available data FDA presented the commu-
nications warning that statin therapy had been 
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associated with increases in levels of fasting se-
rum glucose and HbA1c [31, 40].
Expert opinion
For patients on statin therapy, there are no 
reasons to stop taking statins (even if NOD is 
diagnosed), however careful risk stratification 
before introducing statin therapy should always 
be performed. 
Statins should be used in secondary preven-
tion patients, as the CV benefits significantly 
outweigh the risk of NOD. 
There has been a  debate whether statins 
should be used for primary prevention among pa-
tients with a relatively low baseline CV risk. In this 
group of patients introducing statins should be 
considered individually after careful estimation of 
CV risk and treatment adverse events risks, when 
non-pharmacological therapy is not effective.
Other rare statin-associated adverse effects
Despite the fact that SAMS are the most com-
mon observed adverse effects, patients on statins 
may also present with other side effects, which 
might reduce their quality of life, and might require 
a reduction of dose or statin discontinuation [41]. 
It has been reported that these AEs may affect less 
than 1 in 100 people. The most common observed 
statin-related side effects with the information on 
their prevalence are presented in Table I.
Conditions and populations at high risk  
of statin intolerance
Physical activity and statin intolerance 
Regular physical activity has advantageous ef-
fects on the CV system and reduces CVD mortal-
ity [72, 73]. However, problems (muscle pain, in-
creased CK activity) may occur when statins are 
prescribed for patients taking regular exercise 
(e.g. sportsmen), or when patients start healthy 
lifestyle, including physical exercise, according to 
recommendations [74–76]. In the PRIMO survey, 
the prevalence of statin myopathy was 14.7% in 
those undergoing physical activity and 10.8% in 
less active subjects [23]. The Boston marathon 
runners on statins had much higher CK levels and 
enhanced susceptibility to muscle injury during 
exercise, than those not taking statins [77]. 
Thompson et al. also noticed that statin therapy 
might exacerbate exercise-induced skeletal mus-
cle injury even after less intense training (45 min 
of downhill treadmill walking (–15% grade) at 65% 
of their predetermined maximum heart rate) [78]. 
Table I. Statin-related side effects that have been described in the literature
Organ/systems Side-effects of statins
Respiratory ↑ Risk of interstitial lung disease by 0.01–0.4% [42]
↑  Risk of upper respiratory tract infection by 1–16%, ↑ risk of pharyngitis by 3–13%, rhinitis  
by 1–11%, sinusitis by 2–7%, bronchitis by 2%, cough by 1–2% [43]
Neurologic and 
psychological 
effects
↑  Risk of suicide [44], aggressive behavior [45]
↑  Headache by 2–17%, asthenia by 1–4%, dizziness by 1–4%, fatigue by 1–4% [43]
↑  Risk of depressive disorder in stroke patients [46]
↑  Risk of hemorrhagic stroke (adjusted hazard risk (HR) 1.66, 95% CI: 1.08–2.55) [47]
Severe irritability [48], insomnia, somnolence, agitation, confusion, hallucinations [49] and 
nightmares [50]
Endocrine ↑  Risk of NOD from 9–27% [36, 38, 39, 51]
Intensive-dose statin therapy is associated with a 12% higher incidence of NOD compared  
with moderate-dose statin therapy [38, 51]
Gastrointestinal 
tract
↑  Constipation, diarrhea, dyspepsia, flatulence heartburn, nausea vomiting [43]
Hepatic < 1.5% hepatotoxicity in coronary artery disease patients in 5 years [1]
↑  Activity of liver enzymes [27, 28]
Skin ↑  Risk of alopecia [52], lichenoid eruption [53], dermographism [54], chronic urticaria [55], 
toxic epidermal necrolysis [56] and rash by 1–4% [57]
Eye ↑  The risk of cataract by 27% [58]
↑  Diplopia, ptosis and ophthalmoplegia [59]
Renal ↑  Risk of acute renal failure [60], ↑ proteinuria [61]
Reproductive Erectile dysfunction [62], decrease libido [63], gynecomastia [64], ↓ testosterone levels  
by 10.3% and by 7.5% respectively after 48 weeks of statins [65]
Blood ↑ Risk of thrombotic thrombocytopenic purpura (TPP) [66–68]
Bones and joints Tendinitis, arthralgia, arthritis, lupus, polymyalgia rheumatica [69–71]
M. Banach, M. Rizzo, P.P. Toth, M. Farnier, M.H. Davidson, K. Al-Rasadi, W.S. Aronow, V. Athyros, D.M. Djuric, M.V. Ezhov, R.S. Greenfield,  
G.K. Hovingh, K. Kostner, C. Serban, D. Lighezan, Z. Fras, P.M. Moriarty, P. Muntner, A. Goudev, R. Ceska, S.J. Nicholls, M. Broncel,  
D. Nikolic, D. Pella, R. Puri, J. Rysz, N.D. Wong, L. Bajnok, S.R. Jones, K.K. Ray, D.P. Mikhailidis
6 Arch Med Sci 1, February / 2015
The cross-sectional analysis of over 10,000 pa-
tients showed that increased physical fitness and 
statin therapy are independently associated with 
decreased mortality, but an accumulation advan-
tage on premature mortality through combination 
of statin therapy and exercise training was ob-
served [79]. 
The mechanisms responsible for these associa-
tions are poorly understood. In an animal model of 
statin-induced myopathy, administration of sim-
vastatin impaired phosphatidylinositol 3-kinase 
(PI3k)/Akt signaling in muscle, inducing ubiquitin 
and lysosomal proteolysis through up-regulation 
of the FOXO downstream target genes of mus-
cle atrophy such as cathepsin-L mRNA, muscle 
RING finger-1 (MuRF-1), and F-box (MAFbx), and 
dephosphorylation of the forkhead box protein 
O  (FOXO) (1 and 3) transcription factors [80]. In 
skeletal muscle tissue statin therapy can cause 
mitochondrial dysfunction limited typically to 
complex I of the respiratory chain, which increas-
es mitochondrial NADH and the intracellular redox 
potential (NADH/NAD+  ratio), activates pyruvate 
dehydrogenase kinase (PDK), and inhibits flux via 
the pyruvate dehydrogenase complex (PDC) [81, 
82]. Another possible mechanism for statin-in-
duced myopathy during exercise might be the 
down-regulation of atrogin-1 gene expression, 
a critical component of the ubiquitin proteasome 
pathway and of muscle protein catabolism [83]. 
Inflammation, exercise-induced irisin secretion, 
a  myokine modulating the impact of exercise 
on adipocyte browning, reduced sarcolemmal or 
endoplasmic reticulum cholesterol, depletion of 
intracellular cholesterol leading to increased cal-
cium influx, increased myocellular concentrations 
of cholesterol and plant sterols, modified signal 
transduction and metabolism due to decreased 
mevalonic acid and its metabolite concentrations 
as well as vitamin D deficiency or coenzyme Q10 
deficiency might also increase the probability of 
statin therapy influence on the capacity of skel-
etal muscle to conform to the stress of exercise 
training [84, 85]. 
The studies, which analyzed the risk and bene-
fits of combining statins and exercise, are limited. 
Using a new approach that lower statin dosage to 
permit uncompromised exercise training might 
be a  solution for these patients [27]. However, 
there are at least few questions that need to be 
addressed in future studies. First, how to manage 
patients on intensive regular training (or sports-
men) with high CV risk who require moderate- to 
high-intensity statin therapy. Second, whether we 
should discontinue statin therapy or reduce the 
dose before intense exertion [86]. 
Expert opinion
In individuals with regular intense physical 
exertion one should consider low to moder-
ate-intensity statin therapy. 
In patients on statin therapy, the reduction 
of dose or therapy discontinuation should be 
considered for at least 2 days before predict-
ed intense physical exertion. Any such decision 
should be balanced with the risk of discontinu-
ing statins.
Thyroid diseases and statin intolerance
Statin treatment in the presence of hypothy-
roidism increases the risk of skeletal muscle toxic-
ity [87]. These unwanted effects of statins do not 
correlate with the degree of cholesterol lowering 
effect of the compound used (drug class effect) 
but are dose-related [87, 88], and are related to 
the impairment of mitochondrial function and 
muscle calcium homeostasis [89].
Data from the National Health and Nutrition 
Examination Survey (NHANES) indicates that hy-
pothyroidism occurs in 0.3–0.4%  persons in the 
US, while subclinical hypothyroidism may occur 
in 4.3–8.5% of the general population [90]. It has 
been shown in an animal model that hypothyroid-
ism promotes an increase in oxygen consumption 
by skeletal  muscle  mitochondria and induces an 
increase in sarcoplasmic reticulum calcium [91]. 
Thus, hypothyroidism predisposes to statin-in-
duced muscle toxicity and substantially increases 
the risk of muscle symptoms through the same 
mechanisms as in “non-thyroid” patients [91].
Given that patients with hypothyroidism have 
been excluded from statin clinical trials there are 
limited data regarding the incidence of statin 
muscle toxicity in patients with hypothyroidism 
[92–97]. In hypothyroid patients, myopathy with 
mild elevation of serum CK activity is not rare 
and in a few cases might take the form of overt 
rhabdomyolysis even in patients not on statin 
treatment. However, if statin treatment is added it 
seems that the risk of muscle-related side effects 
increases markedly [91–97]. It is therefore recom-
mended that a clinical examination, thyroid-stim-
ulating hormone (TSH) and thyroxine levels mea-
surement should be performed before statin 
treatment initiation. This is in agreement with the 
recent ACC/AHA lipid guidelines, which suggests 
that the patients prior to statin treatment initia-
tion should always be evaluated for factors that 
might increase the risk for muscle symptoms (e.g. 
hypothyroidism) [1].
If TSH is > 10 mIU/l statins should not be pre-
scribed until TSH returns to levels < 4 mIU/l, after 
thyroxine administration [98]. Given that hypo-
thyroidism is the second most incident cause of 
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secondary dyslipidemia, there might be no need 
for statin treatment after effective thyroxine treat-
ment. Hypothyroidism might also emerge during 
long-term statin treatment [99]. In this case af-
fected patients might develop symptoms or signs 
suggestive of myopathy attributed in most cases 
to statin therapy [99]. These patients should be 
tested for hypothyroidism again and discontinue 
statin treatment [99]. 
Data suggests that subclinical hypothyroidism 
(SCH) (TSH levels > 4 and < 10 mIU/l) is related 
to an unfavorable lipid profile, and levothyrox-
ine replacement therapy may also be prescribed 
in these patients [100]. Some data suggest that 
levothyroxine replacement therapy may exert 
a beneficial effect on total cholesterol (TC), LDL-C 
and other predictors of vascular risk in SCH [100]. 
Furthermore, it appears that in SCH, statins with 
or without levothyroxine, can improve endothelial 
function and reduce carotid intima media thick-
ness, reliable markers associated with CVD risk 
[101]. However, statins may be related to muscle 
symptoms even in patients with SCH [102]. In 
most cases the clinical characteristics are mild, 
and patients may only exhibit raised muscle en-
zyme activities or symptoms of mild myalgia 
and myopathy [102], which usually improve after 
statins discontinuation [7]. Nevertheless, there 
have been reports of severe rhabdomyolysis as-
sociated with acute renal failure requiring renal 
replacement therapy after using high-dose statins 
in a patient with SCH [102]. 
Expert opinion
A clinical evaluation and TSH and thyroxine 
should be performed at baseline prior to start-
ing statin treatment. 
Clinical (TSH > 10 mIU/l) or subclinical (TSH 
= 4–10 mIU/l) hypothyroidism requires thyrox-
ine substitution treatment for at least 3 months, 
with TSH normalization; if there is residual dys-
lipidemia and statin therapy is necessary this 
could be introduced after thyroid function nor-
malization.
Alcohol consumption and statin intolerance
Currently there is limited data on the adverse 
effects of alcohol consumption on statin treat-
ment. The majority of patients on statins do not 
abuse alcohol. It was shown that alcohol misuse 
was associated with increased risk for statin 
non-adherence [103, 104]. It can be assumed that 
high doses of alcohol provoke liver dysfunction 
and increase the risk of myopathy in patients on 
high-intensity statin therapy [104]. However, in 
the Post-Coronary Artery Bypass Graft (CABG) tri-
al all patients were randomly assigned to  lovas-
tatin  in low (mean 4 mg) or high (mean 76 mg) 
doses, and were categorized by weekly alcohol 
intake to abstinent (< 1 drink), light (1–6 drinks), 
moderate (7–13 drinks), and heavy (≥ 14 drinks) 
drinkers. During follow-up only 7% of men had an 
alanine aminotransferase (ALT) of 80 IU/l or high-
er. The risk of an ALT of 80 IU/l or more was com-
parable between these groups: 8, 10, 9, and 6% 
(p = 0.70), respectively [105].
In a small randomized study involving 26 indi-
viduals with primary hypercholesterolemia, 20 g of 
alcohol tended to increase the half-life, area under 
the curve and the time to reach maximum concen-
tration of fluvastatin at a dose 40 mg/day [106]. 
Most statins are metabolized via cytochrome P450 
3A4 (CYP3A4); rosuvastatin is principally metabo-
lized via CYP2C9 whereas ethanol is converted to 
acetaldehyde by CYP2E1 [107]. Therefore, it seems 
that there is no clear basis for significant pharma-
cokinetic interaction between alcohol and statins 
in humans.
Expert opinion
To reduce the risk of statin intolerance all 
dyslipidemic patients should follow the Europe-
an guidelines on cardiovascular disease preven-
tion in clinical practice (2012) [108]: “Consump-
tion of alcoholic beverages should be limited to 
2 glasses/day (20 g/day of alcohol) for men and 
1 glass/day (10 g/day of alcohol) for women to 
obtain the lowest level of chronic disease risk”.
Liver diseases and statin intolerance
The administration of statins to patients with 
liver diseases has been the forbidden fruit of lipi-
dology for at least 2 decades. This impression was 
based on the belief that statins are hepatotoxic, 
even in the general population, manifested as an 
increase in serum ALT or aspartate aminotransfer-
ase (AST) activities, requiring statin dose reduction 
or discontinuation [109]. During the last decade it 
was established that ALT elevations > 3 times ULN 
occur in < 0.5% for moderate-dose statins and ro-
suvastatin at all doses, and about 1% for 80 mg of 
atorvastatin or simvastatin [110]. However, even 
this might be an overstatement, because in most 
studies, the incidence of ALT increase was simi-
lar in statin and placebo patients, and because of 
the fact that almost 50% of dyslipidemic patients 
requiring statin treatment, might have had estab-
lished non-alcoholic fatty liver disease (NAFLD) 
[111, 112]. For over 20 years a raised ALT during 
statin treatment has been also incorrectly consid-
ered to represent liver disease, which led to a lack 
of statin treatment in high risk CV patients [113]. 
Due to the abovementioned consideration, in 
2012 the FDA suggested that patient follow-up for 
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liver tests are largely irrelevant when prescribing 
statins [31]. Nevertheless, the Liver Expert Panel 
recommends that patients with acute liver dis-
ease (e.g. acute viral hepatitis, alcoholic hepatitis) 
should not take statins until they have recovered 
[109, 114]. In chronic liver disease (CLD) however, 
the experts suggested that the positive effect of 
statin therapy on the halt or even the regression 
of fibrosis or/and cirrhosis, should be further in-
vestigated [109, 114]. Both CLD and CVD are com-
mon and often overlapping that it is inevitable for 
clinicians to deal with the issue of whether or not 
to prescribe statins in patients with CLD, without 
causing liver-related statin intolerance. 
Hepatitis B (HBV) and C virus (HCV) liver 
disease 
Statins should not be prescribed to patients 
with active acute HBV until they have recovered 
from the acute phase and until the serum levels 
of AST, ALT, total bilirubin and alkaline phospha-
tase (ALP) have returned to normal [109, 114]. Pa-
tients with chronic HBV with indications for statin 
therapy should be treated [109, 114], however it 
is recommended to check liver enzymes 2 weeks 
after prescribing a  statin or changing its dose, 
then monthly for 3 months and thereafter, 4 times 
a  year [114]. Statins are rarely responsible for 
acute liver failure (ALF) – e.g. the use of lovastatin 
was reported to be related with ALF in 1/1.14 mil-
lion patient-treatment years, what is similar to the 
rate of idiopathic ALF [114, 115]. Statin treatment 
might be useful in significantly reducing the risk 
of hepatocellular carcinoma (HCC) (even by 28%) 
[116]. Thus, statin use in patients with HBV that 
have a very increased risk of HCC, might substan-
tially reduce this risk. 
Every year, 3–4 million people are infected with 
the HCV and about 150 million people are chron-
ically infected with HCV worldwide, while more 
than 350,000 people die every year from hepatitis 
C-related liver diseases [117]. It has been shown 
that statin treatment in patients with chronic HCV 
infection may contribute to the clearance of the 
virus from the blood [118]. A strong relationship 
between HCV replication and lipid metabolism 
exists and statins are expected to disrupt this as-
sociation [118]. It has been shown that fluvasta-
tin down-regulated HCV replication in cell culture 
[119]. The levels of miRNA 122, which is a  key 
regulator in liver homeostasis and provides HCV 
genomic stability remained at steady state where-
as DCLK1 mRNA levels were considerably reduced 
during fluvastatin treatment. This was important 
because HCV replication was increased with DCLK1 
overexpression [119]. It has been also shown that 
the combination of statins (except pravastatin) 
with interferon exhibited strong inhibitory effects 
on HCV RNA replication [120]. This was the first 
time when statins, especially fluvastatin, were 
shown to be potentially useful as new anti-HCV 
agents in combination with interferon [120], and 
that was confirmed in other studies [121]. Statin 
use (especially simvastatin, lovastatin and ator-
vastatin) in HCV patients is also associated with 
a  28% decrease in  risk of  HCC. This was shown 
in a  study that included 3,480 patients with re-
cently diagnosed HCC and 13,920 control subjects 
without HCC matched for age, sex and follow-up 
length [119]. A systematic review and meta-analy-
sis that included 10 studies reporting 4,298 cases 
of HCC in 1,459,417 patients showed a 33–51% 
adjusted HCC relative risk reduction in statin us-
ers compared with statin abstainers [122]. Similar 
results (up to 48% HCC risk reduction) were ob-
tained in another meta-analysis [123]. 
The use of statins prevents about 33% of 
major CVD events when compared with place-
bo; the number needed to treat (NNT) is 3 [124, 
125]. Statins may cause serious liver disease, in 
1/1,000,000; the number needed to harm (NNH) is 
1 million [118]. The percentage of patients who fail 
to receive statins because of fear of hepatotoxicity 
ranges between 10–30% [126]. On the other hand 
statins contribute to the clearance of viral hepati-
tis [120–122], and substantially reduce the risk of 
HCC [119, 122, 123]. Thus, the fear of a possible 
drug adverse effect, which is extremely rare, might 
be a reason that many patients needlessly suffer 
or die from cirrhosis, HCC or CVD events [126]. 
Moreover, 7% to 29% of liver transplantation can-
didates are denied listing as potential recipients 
because of CVD [127]; they may have been eligible 
for listing if they had been on statin therapy [127]. 
Primary biliary cirrhosis (PBC)
Total cholesterol and LDL-C levels are usual-
ly elevated in the patients with PBC. The issue is 
whether or not this is indeed a  CVD risk factor 
and whether it should be treated [128]. Available 
data suggests that high LDL-C in patients with PBC 
should be considered as a CVD risk factor in a sub-
group of patients with other CVD factors [128]. It 
was shown that low-dose atorvastatin therapy is 
safe at early-stage PBC, effectively reducing TC and 
LDL-C, oxidized LDL and soluble vascular cell adhe-
sion molecule-1 (VCAM-1); moreover, it improves 
vascular function as reflected by flow mediated 
dilatation (FMD), without affecting PBC progres-
sion [129]. It was shown, that simvastatin ther-
apy in patients with PBC is safe and effective in 
reducing TC and LDL-C, also having advantageous 
effects on endothelial function and antioxidant 
status [130]. Thus, statins should be considered 
in PBC patients with additional CVD risk factors or 
overt CVD [129]. Available data has also suggested 
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that statins might have a beneficial effect on PBC 
itself [128–131]. 
Non-alcoholic fatty liver disease (NAFLD) 
and steatohepatitis (NASH)
NAFLD is associated with hypertriglyceri-
demia and reductions in high density lipoprotein 
cholesterol (HDL-C) levels, which may be second-
ary to an increase in the size of very low density 
lipoproteins (VLDL) and LDL particle size/ath-
erogenicity  [132]. Therefore, in NAFLD patients 
statin therapy should be recommended. This 
was a considerable problem in the past because 
physicians were afraid of liver damage if they 
prescribed statins [133]. Therefore, until recently 
there has been no effective treatment for NAFLD/
NASH [134]. In a post hoc analysis of the GREek 
Atorvastatin and Coronary heart disease Eval-
uation (GREACE) study assessed patients with 
established CVD and elevated ALT activity due 
to NAFLD [135]. Atorvastatin treatment (mean 
dose 24 mg/day) improved transaminase activ-
ity as well as the hepatic ultrasound features 
during the 3-year follow-up [135]. This suggest-
ed that NAFLD resolved in most statin-treated 
CVD patients in contrast to those not on a sta-
tin, in whom NAFLD worsened during the 3-year 
follow-up [135]. Atorvastatin also reduced CVD 
morbidity/mortality in patients with abnormal 
transaminase activity due to NAFLD to a greater 
extent than in those on atorvastatin, but with-
out NAFLD (68 vs. 39%, p = 0.007) [135]. A sim-
ilar level of safety, NAFLD resolution and CVD 
benefit of atorvastatin treatment was recorded 
in other categories of high risk patients (with 
dyslipidemia, metabolic syndrome, hyperten-
sion or smoking), both in primary and second-
ary CVD prevention [136–138]. In the prospec-
tive St Francis Heart Study 1,005 participants 
(50–70 years old) were randomized to receive 
either atorvastatin 20 mg, vitamin C 1 g, and vi-
tamin E 1,000 IU or placebo [139]. The results 
showed that atorvastatin, combined with anti-
oxidant vitamins, significantly reduced the risk 
hepatic steatosis by 71% in healthy individuals 
with NAFLD at baseline during a 4-year follow-up 
[139]. The post hoc analysis of the Incremental 
Decrease in End Points Through Aggressive Lip-
id Lowering (IDEAL) study, compared intensive 
(80 mg of atorvastatin) vs. moderate (20–40 mg/
simvastatin) statin therapy in CVD patients with 
normal or elevated baseline ALT activity [140]. 
The results showed that in patients with mod-
erate elevations of ALT activity statins were safe 
and reduced ALT activity by  13.4 ±27.5  IU/l in 
those on atorvastatin 80  mg/day (p < 0.0001) 
and 8.8 ±28.8 IU/l (p = 0.007)  in those on sim-
vastatin 20–40 mg/day [140]. 
All the above suggest that moderate elevations 
in liver enzyme activity in high CVD risk patients 
should not be a barrier to prescribe statins, possi-
bly even at higher doses. Physicians are still afraid 
of using statins in NAFLD patients. This approach 
should be changed for at least two reasons: one is 
that statins seem to be an acceptable treatment 
of NAFLD itself (at least in patients with dyslipid-
emia, which includes the vast majority of NAFLD 
patients), and second because NAFLD patients are 
exposed to increased CVD risk and they seem to 
benefit from statin therapy more than those with-
out NAFLD [141]. Finally, it is important to the note 
that more NAFLD patients die of a vascular cause 
than a hepatic cause [142]. 
Expert opinion
The authors of this position paper recom-
mends more frequent ALT/AST monitoring in 
patients with CLD: every month during the first 
3 months of therapy and 4 times per year there-
after.
In CLD patients we recommend stopping sta-
tin therapy if AST/ALT activities rise ≥ 2 times 
the baseline value. After AST/ALT activities 
return to normal/baseline values, it is recom-
mended to consider another statin in order to 
establish whether patient is (liver) statin intol-
erant.
With regard to HBV, HCV and PBC, there are 
common benefits related to statin therapy in 
high risk CV patients. Statins also confer a more 
efficient treatment of viral hepatitis and it is re-
lated with reduced risk of cirrhosis and HCC.
In patients with NAFLD/NASH statin treat-
ment is safe, contributes to the resolution of 
NAFLD/NASH, and substantially reduces CVD 
risk to a level higher than in those with normal 
liver function.
Kidney diseases and statin intolerance 
The Task Force for the management of dys-
lipidemias of the ESC/EAS included pre-existing 
renal disease among the clinical factors that 
predispose patients to a higher incidence of sta-
tin intolerance [27]. Moreover, the presence of 
dyslipidemia in these patients might enhance 
the rate of decline in renal function and chron-
ic kidney disease (CKD) progression, generally 
by raising the inflammation and the oxidative 
stress in the renal microenvironment [143–146]. 
In  the post-hoc  analyses of randomized con-
trolled trials (RCTs) the benefits of statins in 
myocardial infarction (MI) also extend to pa-
tients with mild-to-moderate renal insufficiency 
[147], but these patients are more prone to CVD 
than progress to end-stage kidney disease [147]. 
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The efficacy of statins in dialysis or severe re-
nal insufficiency patients following a MI is less 
known, although statins have not been proven 
to modify the main CV and mortality outcomes 
in primary prevention in hemodialysis patients 
[148]. Dormuth et al. evaluated the association 
between the potency of statins and acute kidney 
injury (AKI) and noticed 34% higher rate of hos-
pitalization for AKI in the participants on high-
er compared with lower doses of statins during 
the first 120 days of treatment [149]. A  recent 
meta-analysis, which included 9 RCTs with 5212 
patients with and without acute coronary syn-
drome evaluated the potential of statins in pre-
vention of contrast-induced acute kidney injury 
(CI-AKI). The results proved that pre-procedural, 
short-term intensive statin therapy substantial 
reduced CI-AKI in ACS patients, but the role of 
statins in non-ACS patients still requires further 
exploration [150]. 
Patients with CKD might have increased sus-
ceptibility to develop statin intolerance since 
multiple abnormalities like endothelial dysfunc-
tion, enhanced oxidative stress, systemic inflam-
mation, electrolyte imbalances, or proteinuria are 
simultaneously present [151, 152]. Recent Kid ney 
Disease: Improving Global Outcomes (KDIGO) 
guidelines regarding the use of cholesterol low-
ering medications in adults and children with 
known CKD stated the potential benefits of 
a  new strategy named fire-and-forget for CKD 
patients, suggesting not to measure LDL-C un-
less the results would alter management [153]. 
In other words, physicians may choose to per-
form follow-up measurement of lipid levels in pa-
tients for whom these measurements are judged 
to favorably influence adherence to treatment or 
other processes of care [153]. Moreover, KDIGO 
guidelines recommended statin or statin/ezeti-
mibe therapy in all individuals aged ≥ 50 years 
with eGFR < 60 ml/min/1.73 m2, and not recom-
mend initiation of statin therapy in dialysis or 
kidney transplantation patients [153]. Finally, 
concerning the safety of the statin therapy, the 
KDIGO Work Group suggests that, due to lack of 
evidence that the risk of liver dysfunction dif-
fers in people with CKD, as compared with those 
without, baseline levels of transaminases should 
be measured before initiating statin treatment, 
however routine follow-up measurements are 
not recommended [153]. Similarly, they do not 
recommend measurement of CK activity at base-
line or during follow-up, unless the patient de-
velops symptoms suggestive of myopathy [153].
Expert opinion
Patients with CKD are at higher risk of statin 
intolerance due to several abnormalities, includ-
ing endothelial dysfunction, enhanced oxidative 
stress, systemic inflammation, electrolyte imbal-
ances, proteinuria, as well as use of concomitant 
therapies. 
The authors of this position paper support 
the KDIGO guidelines on statin safety in CKD 
patients and recommends measurements of base-
line ALT/ASP activity before initiating statin treat-
ment without follow-up measurements, and do 
not recommend measurements of CK activity at 
baseline or during follow-up, unless the patient 
develops symptoms suggestive of myopathy.
Elderly patients and statin intolerance
Aging causes changes in drug pharmacokinet-
ics and pharmacodynamics, which may increase 
drug concentration in elderly patients, increasing 
the risk of adverse effects [154, 155]. Physiologic 
changes with aging include absorption, distribu-
tion, metabolism and excretion [154]. With aging, 
there is a decrease in lean body mass and in total 
body water, causing a reduction in volume of dis-
tribution (V
d
) of hydrophilic drugs [156]. This caus-
es higher plasma concentrations of hydrophilic 
drugs in the elderly [154]. The increased propor-
tion of body fat that occurs with aging also causes 
an increased V
d of lipophilic drugs [154]. The level 
of a1-acid glycoprotein increases, and plasma al-
bumin concentration tends to be reduced in the 
elderly [157]. Reduced liver mass, hepatic blood 
flow, and hepatic metabolic capacity observed in 
the elderly causing accumulation of metabolized 
drugs [154]. Additionally decreased GFR, renal tu-
bular function, and renal blood flow is a reason of 
accumulation of drugs cleared by the kidney [154]. 
Changes in V
d and/or clearance due to aging can 
affect the half-life of a drug, and an increased half-
life means a longer time until steady state condi-
tions occur [154]. There might also be an initial 
delay for the maximum effects of the drug to oc-
cur and prolonged adverse effects [154]. Impaired 
hemostasis, reduced chemoreceptor and barore-
ceptor sensitivity, and reduced b-receptor sensitiv-
ity, as well as comorbidities and multiple medica-
tions are other major factors that might influence 
drug effects in elderly patients [154–157].
Differences in statin metabolism also influence 
potential drug interactions [158]. Atorvastatin, lo-
vastatin, and simvastatin are metabolized primar-
ily by the isoenzyme P3A4 of cytochrome P450 
[158]. Inhibitors of cytochrome P3A4 (CYP3A4), 
which may lead to statin-associated adverse 
effects (and statin intolerance) include, among 
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other, amiodarone, cimetidine, clarithromycin, 
cyclosporine, danazol, erythromycin, diltiazem, 
flu conazole, fluoxetin, fluvoxamine, gemfibrozil, 
grapefruit juice, indinavir, itraconazole, ketocona-
zole, metronidazole, nefazodone, nelfinavir, niacin, 
ritonavir, verapamil, voriconazole and zafirlukast 
[158]. When administered with verapamil or 
amiodarone, the maximum daily dose of simvas-
tatin used should be 20 mg to minimize the risk 
of myopathy [158]. When administered with cy-
closporine, danazol or gemfibrozil, the maximum 
daily dose of simvastatin used to minimize the risk 
of myopathy should be only 10 mg [158]. Bleeding 
or prolonged prothrombin time has been reported 
in patients taking statins metabolized by CYP3A4 
treated concomitantly with warfarin [158]. Rhab-
domyolysis and acute renal failure may possibly 
be caused by administering drugs, which inhibit 
CYP3A4 such as cyclosporine, gemfibrozil, niacin, 
and erythromycin, to elderly patients on statins 
metabolized by CYP3A4 [154]. Rosuvastatin has 
minimal metabolism by CYP2CP and CYP2C19 and 
has biliary excretion [159]. Pravastatin is metabo-
lized by sulphation, biliary excretion, and urinary 
excretion [159]. Fluvastatin is metabolized by 
CYP2C9, CYP2C8, and CYP3A4, and inhibitors of 
CYP2C9 seem to be the most important in increas-
ing myopathy risk in patients treated with fluvas-
tatin [159]. Pitavastatin has minimal metabolism 
by CYP2C8 and CYP2C9 and has lactonisation and 
biliary excretion [159].
In elderly persons, the hydrophilic statins 
(pravastatin and rosuvastatin) are more likely to 
reach increased serum levels. The lipophilic statins 
are likely to cause increased availability because 
of the prolonged half-life caused by an increased 
proportion of total body fat [160]. A reduction in 
hepatic blood flow in elderly persons and a  re-
duction in oxidative metabolism through the cy-
tochrome P450 system in elderly persons may 
result in reduced clearance of many drugs leading 
to increased serum levels of drugs and associated 
toxicity [160]. Statins metabolized through path-
ways other than CYP3A4 may have fewer drug in-
teractions and adverse effects in the elderly [160].
In the Heart Protection Study (HPS) 5,086 of 
the 20,536 men and women were aged 70 to 80 
years at study entry [161]. Muscle symptoms were 
observed in only 0.5% of patients treated with 
simvastatin vs. 0.5% treated with placebo [161]. 
Rhabdomyolysis developed in this study in 5 of 
10,269 persons (0.05%) treated with simvastatin 
vs. 3 of 10,267 persons (0.03%) treated with pla-
cebo. Statin discontinuation because of elevated 
liver enzymes was observed in 0.5% of patients 
treated with simvastatin vs. 0.3% treated with 
placebo [161]. In the Pravastatin in elderly indi-
viduals at risk of vascular disease (PROSPER) trial, 
5,804 men and women were aged 70 to 82 years 
at study entry [162]. Study drug discontinuation 
because of adverse effects was similar in persons 
treated with pravastatin or placebo. No person de-
veloped rhabdomyolysis or a CK activity increased 
10 times the ULN [162]. In older persons in the 
Treating to New Targets (TNT) trial the incidence 
of a > 3 times increase in aminotransferase above 
normal was 1.3% in persons treated with ator-
vastatin 80 mg daily vs. 0.1% in the group with 
atorvastatin 10 mg/day [163]. No person devel-
oped a serum CK activity increased 10 times the 
ULN [163]. A meta-analysis of RCTs on the efficacy 
and safety of statin monotherapy in 51,351 pa-
tients showed no significant difference in study 
drug discontinuation between patients treated 
with statins vs. placebo [164]. Musculoskele-
tal complaints were present in 27% of patients 
treated with statins vs. 26% of patients treated 
with placebo (p < 0.01). ALT/ASP level > 3 times 
ULN was present in 0.5% treated with statins vs. 
0.4% treated with placebo, and serum CK activity 
increased 10 times the ULN was present in 0.1% 
treated with statins vs. 0.1% treated with placebo 
(p > 0.05 for both) [164]. However, as it has been 
mentioned above, in all these trials most patients 
with any statin associated AEs were excluded 
during the recruitment period. 
Because increased adverse effects from statins 
may occur in the elderly due to many different fac-
tors and conditions, one must be cautious in us-
ing the highest dose of statins in elderly patients 
[165]. Since 2011 the FDA has not recommended 
simvastatin 80 mg daily because of the increased 
risk of myopathy, including rhabdomyolysis [1]. 
Hydrophilic statins may penetrate muscle tissue 
less than lipophilic statins and may be less likely 
to cause myopathy in elderly patients [165, 166]. 
If severe illness, major surgery, or major trauma 
occurs in an elderly person, it is prudent to stop 
statin therapy until the person recovers [165]. 
However, it should be also emphasized, that any 
such decision should be carefully balanced with 
the risk of discontinuing statins [86].
Statin therapy is generally well tolerated in the 
elderly and is associated with a  reduction in ma-
jor CV events [155, 167]. However it needs to be 
emphasized that in the relatively few individuals 
> 75 years of age who were included in RCTs of 
high- vs. moderate-intensity statin therapy, there 
was no clear evidence of an additional reduction in 
atherosclerotic CVD events from high-intensity sta-
tin therapy [1]. Moreover, individuals > 75 years of 
age did experience a reduction in CVD events in the 
available trials of mostly moderate-intensity statin 
therapy, compared with controls [1]. Therefore, tak-
ing the above into account (as well as all the risk 
factors of statin intolerance in this group of pa-
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tients) moderate-intensity statin therapy (e.g. rosu-
vastatin 5–10 mg) should be considered for individ-
uals > 75 years of age with clinical atherosclerotic 
CVD according to the ACC/AHA lipid guidelines [1]. 
Expert opinion
Elderly patients are at a higher risk of statin 
intolerance. 
Statin therapy should be started when clin-
ically appropriate, especially if the benefits on 
CVD prevention outweigh potential risks.
The authors of this position paper recom-
mend discontinuing statin therapy in case of se-
vere illness, major surgery, or major trauma until 
the person recovers. Any such decision should be 
balanced with the risk of discontinuing statins.
Hydrophilic statins at moderate-intensity 
doses should be first considered in elderly pa-
tients with CVD. 
Rheumatic diseases and statin intolerance 
Statins might be generally safely administered 
in rheumatic diseases with concomitant CVD. 
Moreover, anti-inflammatory properties of statins 
can positively affect the course of systemic dis-
ease, such as rheumatoid arthritis and osteopo-
rosis without an increase in any AEs [168, 169]. In 
a large cross-sectional study among 5170 partici-
pants without arthritis, the unadjusted prevalence 
of musculoskeletal pain was significantly higher 
for statin users reporting pain in any region (23% 
among statin users, compared with 18% among 
those not using statins, p = 0.02) and in the low-
er extremities (12 vs. 8%, p = 0.02). Conversely, 
among 3058 participants with arthritis (mainly 
osteoarthritis), statin use was not associated with 
higher musculoskeletal pain in any region. The 
similar results were obtained after adjusting for 
potential confounders [170]. 
Several case/non-case studies showed that 
statins might have been significantly associated 
with an increased risk of polymyalgia rheumatica 
(n = 327 cases; reporting odds ratio (ROR) 14.21) 
[69], rheumatoid arthritis (n = 508 patients; ad-
justed OR = 1.71, p = 0.007; a trend between the 
potency of statin treatment and the risk of RA 
was observed) [70] and lupus erythematosus 
(OR = 1.67) [71]. In the last study [71] cases were 
defined as drug-induced lupus reports. Non-cases 
were defined as all reports of other adverse drug 
reactions (ADRs). Among 235,147 ADR reports, 
232 were drug-induced lupus. Exposure to statins 
was present in 17 (7.3%) cases and in 10,601 
(4.7%) non-cases. Reporting odds ratio (ROR) for 
statin exposure associated with lupus erythema-
tosus was 1.67 (ROR was > 1 for each statin but 
fluvastatin) [71]. Taking into account the small 
number of cases with statin therapy (n = 17) these 
results should be further confirmed in other stud-
ies. In the meta-analysis by Noel [171], the author 
investigated the link between statin therapy and 
the risk of drug-induced autoimmune reactions, 
including lupus erythematosus; 28 cases of sta-
tin-induced autoimmune diseases were included 
in the analysis (systemic lupus erythematosus 
was reported in 10 cases and polymyositis in 
14 cases). The mean time of exposure before dis-
ease onset was 12.8 ±18 months; range 1 month 
to 6 years. In many patients, antinuclear antibod-
ies were still positive many months after clinical 
recovery. A  lethal outcome has been recorded in 
2 patients despite aggressive immunosuppressive 
therapy [171]. The authors concluded that long-
term exposure to statins might be associated with 
drug-induced lupus erythematosus and other au-
toimmune disorders [171], however further stud-
ies are necessary to confirm it as well as to find an 
optimal way to manage these patients.
Finally, strong epidemiologic evidence demon-
strates that in rheumatic disease, including rheu-
matoid arthritis and systemic lupus erythematosus, 
there is a  premature, rapidly progressing athero-
sclerosis development, followed by CV complica-
tions [172]. Therefore, the discontinuation of sta-
tin therapy in these patients might be associated 
with significant increased risk of CV and all-cause 
mortality [173]. De Vera et al. aimed to evaluate 
the impact of statin discontinuation on CVD and 
all-cause mortality in a  population-based cohort 
of patients with rheumatoid arthritis [173]. Statin 
discontinuation was defined as persistent nonuse 
for ≥ 3 months during the therapy course. Over 
16,144 person-years of follow-up in the cohort of 
4,102 incident statin users, the authors document-
ed 198 deaths due to CVD and 467 deaths overall. 
Adjusted hazard ratios for the association of statin 
discontinuation with death were 1.60 for CVD mor-
tality and 1.79 for all-cause mortality. The associa-
tion between statin discontinuation and mortality 
outcomes was not modified by timing of the first 
statin prescription, age and sex [173]. It can there-
fore be assumed that the significant benefits of 
statins outweigh the possible risk of systemic dis-
eases development or side effects in patients with 
any rheumatic diseases taking statins. 
Expert opinion
Statins should always be considered in pa-
tients with rheumatic diseases and high CVD risk. 
Rheumatic diseases increase the risk of sta-
tin intolerance e.g. due to often elevated CK 
activity at baseline. Individualization of therapy 
and collaboration with the rheumatologist in 
the treatment process is mandatory. 
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Major surgery and statin intolerance
At present, most evidence suggests that statin 
therapy does not increase the risk of any complica-
tions associated with cardiac and non-cardiac ma-
jor surgery. In a large meta-analysis (n = 31,725), 
preoperative statin exposure significantly reduced 
early mortality (OR = 0.57), stroke (OR = 0.74) and 
atrial fibrillation (OR = 0.6) after cardiac surgery 
[174]. In other study, which included 213,347 old-
er patients who underwent major elective surgery, 
statin therapy was associated with 16% lower risk 
of AKI and 21% lower risk of mortality [175]. In 
a recent single-institution study 7,777 of non-car-
diac operations were analyzed [176]. Procedure 
type included general surgery (33.5%), breast/en-
docrine (9.5%), colorectal (19.7%), hepatobiliary/
pancreatic (5.1%), orthopedic (2.6%), skin/ear-
nose-throat (1.9%), thoracic (0.7%), upper gas-
trointestinal (8.4%) and vascular cases (118.6%). 
Preoperative statin use was present in 10.5% of 
total cases. The use of statins was associated 
with decreased major, non-cardiac complications 
(OR = 0.62; p < 0.001), respiratory complications 
(OR = 0.63; p = 0.017), venous thromboembolic 
events (OR = 0.41; p = 0.044) and infectious com-
plications (OR = 0.65; p = 0.023) [176]. In a  ret-
rospective cohort study of 780,591 patients who 
underwent major non-cardiac surgery, the risk of 
postoperative mortality was considerably lower 
among statin users (unadjusted OR = 0.68) com-
pared with patients without statins [177]. A large 
meta-analysis of 15 studies (n = 223,010) also 
found that perioperative statin therapy was as-
sociated with a substantial reduction of mortality 
risk by 38% after cardiac surgery (p = 0.0001), by 
59% following vascular surgery (p = 0.0001) and 
by 44% after non-cardiac surgery (p < 0.01) [178].
Sudden withdrawal of perioperative statins 
might result in adverse clinical outcomes [179]. 
Statin withdrawal more than 4 days after aortic 
surgery is associated with a 3-fold higher risk of 
post-operative myocardial ischemia [180]. A  po-
tential limitation of perioperative statin use is the 
lack of a parenteral formulation; therefore, statins 
with a long half-life (e.g. atorvastatin) or extend-
ed release formulations (e.g. lovastatin) should 
be favored in the postoperative period when oral 
intake is not feasible [181]. A concern relating to 
the use of perioperative statin therapy has been 
the risk of statin-induced myopathy and rhabdo-
myolysis. There are numerous perioperative fac-
tors that might increase the risk of statin-induced 
myopathy, e.g. the impairment of renal function 
after major surgery, myositis, liver dysfunction 
and multiple drugs use during anesthesia [179, 
181]. Furthermore the use of analgesic drugs and 
post-operative pain may mask signs of myopathy 
[181]. It is especially important, as failure to de-
tect statin-induced myopathy may then lead to 
the statin being continued and the subsequent 
development of rhabdomyolysis and acute renal 
failure [181]. Therefore, the monitoring of CK and 
ALT/ASP activity is recommended in patients tak-
ing statins perioperatively [179, 181]. However, 
if any serious complications develop, the statins 
should be immediately discontinued and appro-
priate treatment initiated. According to current 
ESC (2014) guidelines on non-cardiac surgery 
[181], most patients with peripheral artery dis-
ease should receive statins. If they have to under-
go open vascular surgery or endovascular inter-
vention, statins should be continued afterwards 
[181]. In patients not previously treated, statins 
should ideally be initiated at least 2 weeks before 
intervention for maximal plaque-stabilizing ef-
fects and continued for at least 1 month after sur-
gery. In patients undergoing non-vascular surgery, 
there is no evidence to support pre-operative sta-
tin treatment if there is no other indication [181].
Expert opinion
Perioperative statin therapy significantly 
reduces the risk of complications after major 
surgery. The authors of this position paper sup-
port the ESC guidelines on non-cardiac surgery 
(2014). 
The careful monitoring of CK and ALT/ASP 
activity is recommended in patients taking 
statins perioperatively. In case of any serious 
statin-related complications, statin therapy 
should be immediately discontinued.
Definition of statin intolerance
Statin intolerance is widely defined as not be-
ing able to tolerate a registered statin dose, due to 
side effects such as myalgia-myopathy, myositis, 
or elevation of serum liver enzyme activities [182]. 
Statin intolerance has been also described as 
a clinical syndrome with the following character-
istics: (1) incapacity to use statin therapy because 
of appearance of symptoms and/or abnormal 
values of biomarkers at the initiation or at dose 
escalation of statin therapy; (2) no presence of in-
dividual predispositions, such as drug-drug inter-
actions, untreated hypothyroidism, febrile illness, 
that may contribute to statin intolerance [18]. In 
addition, two different clinical patterns have been 
identified: the complete intolerance, when a sub-
ject is intolerant to any statin at any dose, and the 
partial intolerance, when a subject is intolerant to 
some statins at some doses [18]. Further, given 
that there are many statins available, it has been 
proposed that the statin intolerance represents in-
tolerance to the starting dose of one statin and 
any dose of another statin [18]. However, the oc-
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currence of different, non-specific, rare, and prob-
ably idiosyncratic adverse events complicates sta-
tin intolerance diagnosis (and in the consequence 
the management), increasing the risk of long-term 
consequences of statin-related AEs [18].
Statin intolerance represents an increasing 
problem related to the rising number of subjects 
treated with statins, limiting the benefit of such 
therapies for subjects at high CV risk [182]. Mus-
cle symptoms, ranging from mild myalgia to rhab-
domyolysis, are major side effects and a  leading 
cause of statin intolerance [183]; these symptoms 
may occur even in the absence of CK elevation 
(myalgia, myopathy) [20]. However, the defini-
tion of statin-associated muscle adverse effects 
(myopathy) varies between the different orga-
nizations such as ACC/AHA, the National Heart, 
Lung and Blood Institute (NHLBI), FDA, the Euro-
pean Medicines Agency (EMA), the National Lipid 
Association (NLA) (2006 and 2014), and recently 
the EAS [1, 10, 20, 182]. All the details concern-
ing these definitions were clearly presented in the 
supplemental material (Webtable 1) of the recent 
EAS Consensus Panel Statement on Assessment, 
Aetiology and Management [10].
Given that there is currently no widely accepted 
definition of statin intolerance, some authors en-
deavored to use a practical definition in their own 
study. Thus, Sullivan et al. [184] in the GAUSS trial 
with evolocumab defined statin intolerance as the 
inability to tolerate at least 1 statin at any dose 
or an increase in dose above weekly maximums 
of rosuvastatin 35 mg; atorvastatin 70 mg; sim-
vastatin 140 mg; pravastatin 140 mg; lovastatin 
140 mg; or fluvastatin 280 mg, because of intoler-
able myalgia (muscle pain, soreness, weakness, or 
cramps) or myopathy (myalgia plus elevated CK) 
and having symptom improvement or resolution 
with statin discontinuation. Such approach result-
ed in a  population with an unmet medical goal, 
as exemplified by the mean LDL-C > 190 mg/dl, 
24% of subjects with atherosclerotic disease and 
50% at high or moderately high CV risk and even 
84% of all participants were unable to tolerate 
low doses of any statin [184]. The definition did 
not also mention that symptom improvement or 
resolution might often appear after reducing of 
statin dose, without necessity of discontinuing 
of statin therapy [185]. Finally it seems to be too 
complicated for general practitioners and family 
doctors, who for the most part take care of sta-
tin intolerant patients. In the GAUSS-2 trial [186] 
the definition was updated and simplified. Statin 
intolerance was defined as the inability to toler-
ate ≥ 2 statins at any dose or increase the dose 
above the smallest tablet strength because of intol-
erable muscle-related side effects, which resolved 
or improved significantly upon dose decrease or 
discontinuation. The ongoing GAUSS-3 trial [187, 
188] the definition was again changed, and statin 
intolerance was defined as the inability to tolerate 
atorvastatin at an average dose of 10 mg/day and 
unable to tolerate any other statin at any dose due 
to skeletal muscle related symptoms OR the inabil-
ity to tolerate at least 3 statins – one statin at the 
lowest starting average daily dose and any other 
2 statins at any dose due to skeletal muscle relat-
ed symptoms OR documented history of CK eleva-
tion > 10 times the ULN accompanied by muscle 
symptoms while on statin therapy, which resolved 
upon discontinuation AND symptoms resolved 
or improved when statin dose was decreased or 
discontinued. This definition rises at least few 
questions – why the authors decided to mention 
only atorvastatin especially statin intolerance is 
observed relatively often after atorvastatin [23, 
24]. Another question concerns the mentioned 
number of statins (at least 3 – in GAUSS-2 there 
were at least 2 [186]). Finally, it is difficult to agree 
with the statement that statin intolerance should 
be also diagnosed based on the patient’s histo-
ry only, as such case of statin intolerability might 
happen incidentally, accompanied by the con-
dition/situation, which essentially increase the 
risk of statin intolerance (e.g. physical exertion, 
hypothyroidism) [7, 11]. Despite that, GAUSS-3 
trial might bring very important information for 
statin intolerant patients due to the fact that for 
the first time the authors decided to analyze the 
drug’s rechallenge, since there is evidence that 
patients who discontinue statins due to subjec-
tive intolerance are able to tolerate this drug class 
upon rechallenge [7, 11, 187, 188]. In ODYSSEY 
ALTERNATIVE trial [189] with alirocumab statin in-
tolerance was definition was very similar to the 
one used in GAUSS-2 trial: the inability to toler-
ate at least 2 different statins because of unex-
plained skeletal muscle-related symptoms, such 
as pain, aches, weakness, or cramping that began 
or increased during statin therapy and returned to 
baseline when statin therapy was discontinued. 
For each patient to meet this definition one of the 
statins that was discontinued had to have been at 
the lowest approved daily starting dose (i.e., ro-
suvastatin 5 mg, atorvastatin 10 mg, simvastatin 
10 mg, lovastatin 20 mg, pravastatin 40 mg, flu-
vastatin 40 mg, pitavastatin 2 mg); the other 
statin was at any dose. Finally in June 2014 NLA 
Expert Panel on Statin Intolerance suggested the 
following definition: Statin intolerance is a clinical 
syndrome characterized by the inability to tolerate 
at least 2 statins: one statin at the lowest starting 
daily dose (rosuvastatin 5 mg, atorvastatin 10 mg, 
simvastatin 10 mg, lovastatin 20 mg, pravastatin 
40 mg, fluvastatin 40 mg, and pitavastatin 2 mg) 
AND another statin at any daily dose, due to either 
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objectionable symptoms (real or perceived) or ab-
normal lab determinations, which are temporally 
related to statin treatment and reversible upon 
statin discontinuation, but reproducible by rechal-
lenge with other known determinants being ex-
cluded (such as hypothyroidism, interacting drugs, 
concurrent illnesses, significant changes in physical 
activity or exercise, and underlying muscle disease) 
[190]. While it has been a very good attempt of 
statin intolerance definition, it has again few lim-
itations: (1) ‘perceived symptoms’ might not often 
be related to statin therapy, that is why it is so im-
portant to try to confirm that the observed AEs are 
indeed associated with statin therapy, (2) in many 
cases reduction of statin dose is enough to ob-
serve the symptoms resolution or improvement; 
and (3) the inclusion of drug’s rechallenge to the 
definition might underestimate the risk (and num-
ber of patients) of statin intolerance, especially 
there is evidence that patients who discontinue 
statins are able to tolerate these drugs upon re-
challenge [7, 11, 187, 188, 190]. 
In the study with mipomersen, Visser et al. 
[191] suggested the protocol-specified defini-
tion of statin intolerance including myalgia, liver 
enzyme increasing, neurological symptoms and 
other reasons. The subjects were considered to 
be statin intolerant if they were unable to tolerate 
at least 2 different statins due to side effects of 
any kind [190]. Donnelly et al. in their large ob-
servational study of statin prescribing in subjects 
with type 2 diabetes [192] have demonstrated 
that two functional variants, V174A and N130D of 
the SLCO1B1 gene, known to encode organic an-
ion-transporting polypeptide (OATP)-C/OATP1B1 
which regulate the hepatic uptake of statins, are 
associated with statin intolerance. Their defini-
tion of intolerance was derived from statin dis-
continuation, switching or dose reduction and 
may incorporate a  range of side effects, but not 
necessarily related to myopathy or myalgia [192]. 
Both biochemical abnormalities and prescribing 
changes within individuals have been consid-
ered in defining of statin intolerance. Biochemi-
cal abnormalities included those exceeding the 
ULN ranges for both ALT and CK, as determined 
for the age and gender of each subject. Relevant 
prescribing changes included switching statin to 
equivalent or lower dose, dose reduction of the 
same statin, or discontinuation of statin. Statin 
intolerance was defined in two cases: 1) abnor-
mal CK activity (1 to 3 times over the ULN) but 
with normal CK activity before statin therapy; or 
2) abnormal ALT activity, with normal ALT activity 
before statin therapy, and also the cases of an in-
creasing ≥ 50% in ALT activity from baseline was 
considered as abnormal [192]. If these abnormali-
ties have been accompanied by a relevant change 
in prescribing such subjects were defined as intol-
erant. In addition, subjects with normal CK activity 
before a prescribing change were also defined as 
intolerant. On the other hand, the subjects with 
abnormal CK or ALT activity but without change 
in prescribing were defined as neither tolerant 
nor intolerant. The tolerant group was defined as 
subjects with normal CK or ALT activity during the 
period of statin treatment, with no prescribing 
changes and a  consistent statin dose (10 mg of 
simvastatin or greater) [192]. Interestingly, Raju et 
al. pointed out that in the clinical practice statins 
have been associated with several adverse effects 
forcing abrupt discontinuation without consult-
ing a physician and despite the confirmed safety 
and efficacy profile, and this is referred as statin 
intolerance [193]. At this point it is important to 
emphasize the role of nocebo effect (= side effects 
experienced by patients if they anticipate a medi-
cation might be harmful), as an important reason 
of statin discontinuation without consulting with 
a physician, what might overestimate the number 
of patients with statin intolerance [194]. 
As the routine tests or assays that evaluate sta-
tin intolerance or adverse effects (with the excep-
tion of muscle and liver enzyme assays) current-
ly do not exist, there is a large need to unify the 
classification of statin intolerance. Several factors 
mentioned above (subject-related and drug-relat-
ed) which determine statin intolerance should be 
carefully examined and observed before this clin-
ical syndrome can be considered [195]. Before all, 
it should strive to reduce the risk of statin intoler-
ance by: careful comprehensive assessment of the 
patient before treatment, taking into account the 
medical history (illness, concomitant therapy), pa-
tient counseling, informing about possible symp-
toms and ongoing monitoring [18]. Baseline liver 
function tests should be obtained before initiating 
statin therapy and CK activity as well in all sub-
jects at increased risk of myotoxicity. Hypothyroid-
ism and other predisposing conditions should be 
excluded in patients who develop myalgia [196].
The history of statin intolerance should be also 
taken into account. Such subjects may be able to 
tolerate lower dose or another statin. Further, the 
role of exercise testing combined with imaging 
might eventually have a clinical role [196, 197]. 
The correct prevalence of statin intolerance is 
questionable given that many studies have depend-
ed on self-reporting of muscle side-effects without 
expert assessment [197]. We suggest that statin 
intolerance should not be considered immediately 
with occurrence of muscle symptoms particularly 
as well as abnormal biomarker values. Detailed 
examination of biochemical parameters should be 
performed and repeated with careful survey of eti-
ologies of the occurred symptoms. When all other 
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etiologies are excluded (patient and drug-related), 
abnormal values confirmed, the next step should 
be change of statin dose (no more often than ev-
ery 2–4 weeks) or replacement by another statin 
(at suitable dose taking into account CV risk), at 
the time when the subject becomes asymptomat-
ic. Which statin to use will dependent on each in-
dividual situation. If after treatments with several 
statins, at different doses, the muscle symptoms 
(and/or other mentioned above side effects) are 
still intolerable and/or abnormal values of bio-
markers (> 10-fold increased in CK, together with 
increases in serum creatinine) remain, the subject 
can be characterized as intolerant to statin. 
The aim of the present position paper was to 
suggest a  unified statin intolerance definition, 
which should meet two main conditions: (1) to be 
commonly used by the physicians of all specialties 
who manage dyslipidemic patients, and, (2) to al-
low optimal diagnosis and avoid both over- and 
underrepresentation. Finally, we would like to fo-
cus particular attention on the patients’ education 
in order to minimize the risk of a nocebo effect. 
In brief, statin intolerance should generally in-
volve: development of symptoms while on a sta-
tin, resolution of symptoms when the statin is dis-
continued, and recurrence of symptoms when the 
same or a different statin is restarted. Using more 
detailed criteria, statin intolerance is a  clinical 
syndrome that is: (1) characterized by inability to 
use statins for long-term reduction of lipids and/
or cardiovascular risk because of significant symp-
toms and/or biomarker abnormalities that can be 
temporally attributed to the initiation or dose es-
calation of statins; if appropriate, drug withdrawal 
and rechallenge can strengthen the association, 
(2) either “complete” (intolerant to any statin at 
any dose) or “partial” (intolerant to some statins 
at some doses), and, (3) not attributable to estab-
lished predispositions such as drug-drug interac-
tions, and untreated hypothyroidism, etc. 
Unified definition of statin intolerance:
1) the inability to tolerate at least 2 different 
statins – one statin at the lowest starting av-
erage daily dose and the other statin at any 
dose,
2) intolerance associated with confirmed, intol-
erable statin-related adverse effect(s) or sig-
nificant biomarker abnormalities*,
3) symptom or biomarker changes resolution or 
significant improvement upon dose decrease 
or discontinuation,
4) symptoms or biomarker changes not attrib-
utable to established predispositions such as 
drug-drug interactions and recognized condi-
tions increasing the risk of statin intolerance. 
*According to the recent recommendations [10, 20, 198].
The most common diagnostic errors 
There is certainly an inherent reluctance among 
the population in general to be placed on prescrip-
tion medication. Many factors come into play such 
as cost, potential side effects, and the stigma of 
having to take medication over an indefinite peri-
od [199, 200]. Fueling the so-called statin rebellion 
is the unfiltered information on the internet, in-
terpretation of TV advertisements, and exhaustive 
small print package inserts warning of every con-
ceivable side effect. It is no wonder that many pa-
tients claim statin intolerance (nocebo effect). Thus, 
it becomes a daunting task to appropriately diag-
nose and manage the myriad of symptoms that 
are either true statin intolerance or only perceived 
as such and avoiding errors in their diagnosis.
The most worrisome error in the diagnosis of 
statin intolerance involving muscle symptoms is 
not diagnosing the condition when it truly occurs. 
Errors in the diagnosis are not unusual because 
the symptom complex of muscle pain, fatigue, and 
nocturnal cramping are common. Statin-induced 
myopathy affects large muscle groups and is usu-
ally bilateral, symmetrical and may be worsened 
by exercise [20]. Joint pain, often mistaken for 
myalgia is a very unusual side effect of statin use 
and another etiology should be sought [168–170]. 
Muscle symptoms that appear only after a  few 
days is more unusual for statin-related symptoms 
as true statin-related symptoms most commonly 
appear weeks to months after initiation of therapy 
or increase in dose (75% in the first 12 weeks) and 
are more common in patients on high dose ther-
apy and/or who are also taking other medication 
[19]. Muscle symptoms that begin after years of 
statin usage without a medication change are less 
likely to be statin-related [200]. A useful approach 
is to fulfill a modification of so-called Koch’s Pos-
tulates [24], and remove the statin for 2–3(4) 
weeks. Should symptoms subside, re-challenge 
with the same or lower dose of statin. Should the 
symptoms return strong presumptive evidence 
exists that the symptoms are truly statin-related. 
Although it has been reported that statin-related 
symptoms can be present for months after the 
drug is discontinued, this is unusual and suggests 
that an underlying independent muscle disorder 
should be excluded [24, 199, 200]. 
Lastly, the health care providers may initiate 
errors in the diagnosis of statin intolerance. This 
may occur unintentionally as physicians create an 
adverse expectation, when we dutifully point out 
the potential side effects when initiating statin 
therapy [201]. In turn, patients formulate expecta-
tions regarding symptoms. Moreover, as clinicians 
with busy schedules, clearly it is difficult to ex-
amine the many psychosocial barriers present in 
some patients that can be predisposing factors for 
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their statin intolerance. Errors in the diagnosis of 
statin intolerance are often made by accepting the 
diagnosis based a false patient assumption based 
on their history. It is interesting to note that in a re-
cently reported survey, 14% of all patients either 
had no idea why they stopped their statin or re-
ported symptoms categorized as other [202]. The 
Understanding Statin Use in America and Gaps in 
Patient Education (USAGE) survey attempted to 
understand the use of statins in US and gaps in 
patient education, and suggested that improved 
physician-patient communication about the side 
effects and benefits of statins are necessary to im-
prove both adherence and outcomes [199]. In this 
way, errors in diagnosis can be essentially reduced.
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